Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222864
Title: Expert consensus on the management of adverse events of Lorlatinib in the treatment of ALK+ advanced non-small cell lung cancer
Author: Arriola Aperribay, Edurne
Castro, Javier de
García Campelo, Rosario
Bernárdez, Beatriz
Bernabé, Reyes
Bruna, Jordi
Dómine, Manuel
Isla, Dolores
Juan Vidal, Óscar
López Fernández, Teresa
Nadal, Ernest
Rodríguez Abreu, Delvys
Vares, María
Asensio, Úrsula
García, Luis F.
Felip, Enriqueta
Keywords: Medicaments antineoplàstics
Càncer de pulmó
Antineoplastic agents
Lung cancer
Issue Date: 31-Jul-2024
Publisher: Springer Science and Business Media LLC
Abstract: The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts.
Note: Reproducció del document publicat a: https://doi.org/10.1007/s40261-024-01379-7
It is part of: Clinical Drug Investigation, 2024, vol. 44, num. 8, p. 553-576
URI: https://hdl.handle.net/2445/222864
Related resource: https://doi.org/10.1007/s40261-024-01379-7
ISSN: 1179-1918
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Expert consensus on the Management.pdf5.2 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons